Valuation: 4D Molecular Therapeutics, Inc.

Market Cap 657M 589M 542M 491M 917M 62.42B 934M 6.46B 2.59B 32.84B 2.47B 2.41B 104B P/E 2026 *
-2.87x
P/E 2027 * -2.98x
Enterprise Value 462M 414M 381M 345M 645M 43.89B 657M 4.54B 1.82B 23.09B 1.73B 1.7B 72.81B EV / Sales 2026 *
34.9x
EV / Sales 2027 * 15.7x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: 4D Molecular Therapeutics, Inc.

1 day-6.89%
1 week+10.19%
1 month-16.84%
3 months+16.90%
6 months+34.16%
Current year+58.67%
1 week 10.62
Extreme 10.62
13.46
1 month 10.62
Extreme 10.62
14.14
Current year 6.96
Extreme 6.96
16.93
1 year 6.96
Extreme 6.96
16.93
3 years 2.24
Extreme 2.235
36.25
5 years 2.24
Extreme 2.235
36.25
10 years 2.24
Extreme 2.235
55.11
Manager TitleAgeSince
Chief Operating Officer 51 31/03/2018
Chief Executive Officer 64 11/09/2013
Director of Finance/CFO 51 16/11/2025
Director TitleAgeSince
Chairman 64 11/09/2013
Director/Board Member 62 30/11/2015
Director/Board Member 47 28/02/2019
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Founder

-58,333 0.1056%
16/09/26 Exercice

Compliance Officer

4,905 0.0089%
14/09/26 Sell

Founder

-58,333 0.1056%
Change 5-day change 1-year change 3-year change Capi.($)
-6.89%+10.19%+3.48%+10.80% 657M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.38%+7.80%+43.17%+176.57% 39.5B
Weighted average by Cap. +0.17%+5.45%+47.92%+176.39%

Financials

2026 *2027 *
Net sales 13.26M 11.87M 10.92M 9.89M 18.5M 1.26B 18.84M 130M 52.28M 662M 49.75M 48.69M 2.09B 20.63M 18.48M 17M 15.4M 28.79M 1.96B 29.33M 203M 81.37M 1.03B 77.43M 75.79M 3.25B
Net income -289M -258M -238M -215M -403M -27.4B -410M -2.84B -1.14B -14.41B -1.08B -1.06B -45.46B -316M -283M -261M -236M -441M -30.03B -449M -3.11B -1.25B -15.79B -1.19B -1.16B -49.81B
Net Debt -195M -175M -161M -146M -272M -18.53B -277M -1.92B -770M -9.75B -732M -717M -30.74B -334M -299M -275M -249M -466M -31.72B -475M -3.28B -1.32B -16.69B -1.25B -1.23B -52.62B
Projected Income Statement - Annual - 4D Molecular Therapeutics, Inc.
Logo 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Employees
196
Date Price Change Volume
30/10/26 US$11.90 -6.89% 683,493
29/10/26 US$12.78 -1.16% 848,927
28/10/26 US$12.93 +8.11% 1,189,801
27/10/26 US$11.96 +8.43% 1,134,654
26/10/26 US$11.03 +2.13% 1,084,578
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - 4D Molecular Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
11.90USD
Average target price
28.09USD
Spread / Average Target
+136.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - 4D Molecular Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FDMT Stock